Newsroom

NEWS

May 19, 2026

Galux Shows Broadest Target Coverage in Comparative De Novo Antibody Design Study

Read More

NEWS

April 21, 2026

GC Biopharma and Galux Collaborate on AI-designed Autoimmune Antibody Drugs

Read More

NEWS

April 20, 2026

OliX and Galux Partner to Develop AI-based siRNA Delivery Platform

Read More

NEWS

April 15, 2026

Galux to Present Preclinical Data on AI-Designed PD-1/IL-18v Immunocytokine at AACR 2026

Read More

NEWS

February 10, 2026

Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery

Read More

NEWS

February 9, 2026

ISU Abxis and Galux Launch AI-Driven Collaboration to Develop Next-Generation Therapies for Rare Diseases

Read More

NEWS

December 17, 2025

Galux Announces Research Agreement with Boehringer Ingelheim to Advance AI-Driven Protein Design

Read More

NEWS

December 11, 2025

Galux and Seoul National University Develop ‘T-SCAPE,’ an AI for Predicting Immunogenicity of Drug Candidates

Read More

NEWS

December 2, 2025

Galux and Celltrion Enter Strategic Partnership to Co-Develop Next-Generation Multispecific Antibodies for Autoimmune Diseases

Read More

NEWS

November 26, 2025

Galux Achieves Breakthrough by Delivering High-Affinity De Novo Antibodies from Only 50 AI Designs, Marking a New Era in Precision Protein Design

Read More

NEWS

November 14, 2025

Galux and ISU Abxis Sign MOU to Collaborate on AI-Driven Drug Discovery

Read More

NEWS

September 30, 2025

Galux and Woojung Bio Forge Strategic Partnership to Accelerate AI-Driven Therapeutics Development

Read More